A Japanese government panel has approved the world\'s first clinical research using human induced pluripotent stem cells, officials said. The panel of the country\'s Health Ministry has issued approval for governmental scientific research institute Riken and the Foundation for Biomedical Research and Innovation to conduct a clinical research plan to use iPS cells for retinal regeneration, Kyodo News reported Wednesday. Kyoto University Professor Shinya Yamanaka co-won the 2012 Nobel Prize in physiology or medicine for his development of iPS cells, which can grow into any type of human body tissue and are seen as candidates for regenerative medicine and drug development. The clinical research team will try to develop treatment techniques using iPS cells to cure age-related macular degeneration, a condition that can cause sudden vision loss due to retinal damage. The team said it would extract skin cells from several patients, create iPS cells from them, develop them into pigment epithelium of the retina and transplant them into the patients\' retinas. The researchers said they would attempt the transplants next year.
GMT 10:28 2018 Friday ,19 January
Amazon narrows list of 'HQ2' candidates to 20GMT 09:04 2018 Thursday ,18 January
China to step up cryptocurrency crackdownGMT 08:32 2018 Sunday ,14 January
Japan's new crypto-currency crooners sing the bitcoin beatsGMT 09:22 2018 Friday ,12 January
Top European chefs take electric pulse fishing off the menuGMT 20:15 2018 Tuesday ,09 January
ADGM and Bahrain EDB agree to collaborate on fintechGMT 13:45 2018 Tuesday ,09 January
Apple urged to shield kids from iPhone addictionGMT 00:14 2018 Monday ,08 January
John Young, who set records in space sub: with NASA, is dead at 87GMT 08:31 2017 Friday ,21 July
Samsung heiress ordered to pay $7.6 millionMaintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2021 ©
Maintained and developed by Arabs Today Group SAL.
All rights reserved to Arab Today Media Group 2021 ©
Send your comments
Your comment as a visitor